Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal bevacizumab for exudative age-related macular degeneration
2009-016158-42Phase 3Active
- Sponsor
- Azienda ULSS 16 Padova
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bevacizumab in exudative macular degeneration, sponsored by Azienda ULSS 16 Padova. Primary endpoint: Responders after 12 months. Started Nov 2009; status: active.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2009-016158-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016158-42.